Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026

Thu, 04 Jun 2026 11:45:00 -0400

All resolutions recommended by the Board of Directors were adopted, with the exception of the 15th

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, held its Combined General Meeting of June 4, 2026, which was chaired by Mr. Sacha Loiseau, Chairman of the Board of Directors and CEO.

With a quorum of 45.79%, all resolutions recommended by the Board of Directors were adopted, with the exception of the 15th. These notably included:

- the approval of the statutory and consolidated financial statements

Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026

Thu, 04 Jun 2026 11:45:00 -0400

All resolutions recommended by the Board of Directors were adopted, with the exception of the 15th

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

With a quorum of 45.79%, all resolutions recommended by the Board of Directors were adopted, with the exception of the 15th. These notably included:

- the approval of the statutory and consolidated financial statements

Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026

Thu, 04 Jun 2026 11:45:00 -0400

All resolutions recommended by the Board of Directors were adopted, with the exception of the 15th

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

With a quorum of 45.79%, all resolutions recommended by the Board of Directors were adopted, with the exception of the 15th. These notably included:

- the approval of the statutory and consolidated financial statements

Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026

Thu, 04 Jun 2026 11:45:00 -0400

All resolutions recommended by the Board of Directors were adopted, with the exception of the 15th

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

With a quorum of 45.79%, all resolutions recommended by the Board of Directors were adopted, with the exception of the 15th. These notably included:

- the approval of the statutory and consolidated financial statements

Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

Wed, 03 Jun 2026 12:00:00 -0400

Article L233-8-II of the Commercial Code

Article 223-16 of the General Regulations of the AMF

PARIS--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Paris:ALMKT):

Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website: www.maunakeatech.com

Date

Number of shares comprising
the capital in circulation

Total number of voting rights

Gross Total (1)

Article L233-8-II of the Commercial Code

Article 223-16 of the General Regulations of the AMF

PARIS--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Paris:ALMKT):

Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website: www.maunakeatech.com

Date

Number of shares comprising
the capital in circulation

Total number of voting rights

Gross Total (1)

Article L233-8-II of the Commercial Code

Article 223-16 of the General Regulations of the AMF

PARIS--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Paris:ALMKT):

Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website: www.maunakeatech.com

Date

Number of shares comprising
the capital in circulation

Total number of voting rights

Gross Total (1)

Article L233-8-II of the Commercial Code

Article 223-16 of the General Regulations of the AMF

PARIS--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Paris:ALMKT):

Listing: Euronext Growth Paris
ISIN code: FR0010609263, Ticker: ALMKT
Website: www.maunakeatech.com

Date

Number of shares comprising
the capital in circulation

Total number of voting rights

Gross Total (1)

100% of patients achieving Cellvizio-assessed triple healing remained relapse-free over 24 months (0 of 29), versus a ~33% relapse rate among those who did not

A decade of converging, multi-center evidence positions Cellvizio as a differentiated tool to predict outcomes across inflammatory bowel disease (IBD), a therapeutic market with significant potential exceeding $25 billion

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today highlighted the publication of a prospective study in the United European Gastroenterology Journal (Minea et al.1) that strengthens

Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying “Triple Healing”, a Cellvizio®— Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Col

Wed, 03 Jun 2026 11:45:00 -0400

100% of patients achieving Cellvizio-assessed triple healing remained relapse-free over 24 months (0 of 29), versus a ~33% relapse rate among those who did not

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today highlighted the publication of a prospective study in the United European Gastroenterology Journal (Minea et al.1) that strengthens

Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying “Triple Healing”, a Cellvizio®— Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Col

Wed, 03 Jun 2026 11:45:00 -0400

100% of patients achieving Cellvizio-assessed triple healing remained relapse-free over 24 months (0 of 29), versus a ~33% relapse rate among those who did not

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today highlighted the publication of a prospective study in the United European Gastroenterology Journal (Minea et al.1) that strengthens

Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying “Triple Healing”, a Cellvizio®— Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Col

Wed, 03 Jun 2026 11:45:00 -0400

100% of patients achieving Cellvizio-assessed triple healing remained relapse-free over 24 months (0 of 29), versus a ~33% relapse rate among those who did not

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today highlighted the publication of a prospective study in the United European Gastroenterology Journal (Minea et al.1) that strengthens

Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance® Commercial Installation

Wed, 20 May 2026 11:45:00 -0400

IBS-related symptom prevalence in the region is among the highest in the world, reaching an average of 27%

An ideal region uniquely positioned for CellTolerance®’s direct out-of-pocket commercial expansion

First sales confirmed in UAE this quarter

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces a significant milestone in its international expansion, driven by official regulatory approvals in both the United Arab Emirates (UAE) and Turkey, alongside the first commercial sales for CellTolerance® in the region. These authorizations enable

Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance® Commercial Installation

Wed, 20 May 2026 11:45:00 -0400

IBS-related symptom prevalence in the region is among the highest in the world, reaching an average of 27%

An ideal region uniquely positioned for CellTolerance®’s direct out-of-pocket commercial expansion

First sales confirmed in UAE this quarter

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces a significant milestone in its international expansion, driven by official regulatory approvals in both the United Arab Emirates (UAE) and Turkey, alongside the first commercial sales for CellTolerance® in the region. These authorizations enable

Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance® Commercial Installation

Wed, 20 May 2026 11:45:00 -0400

IBS-related symptom prevalence in the region is among the highest in the world, reaching an average of 27%

An ideal region uniquely positioned for CellTolerance®’s direct out-of-pocket commercial expansion

First sales confirmed in UAE this quarter

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces a significant milestone in its international expansion, driven by official regulatory approvals in both the United Arab Emirates (UAE) and Turkey, alongside the first commercial sales for CellTolerance® in the region. These authorizations enable

Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance® Commercial Installation

Wed, 20 May 2026 11:45:00 -0400

IBS-related symptom prevalence in the region is among the highest in the world, reaching an average of 27%

An ideal region uniquely positioned for CellTolerance®’s direct out-of-pocket commercial expansion

First sales confirmed in UAE this quarter

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces a significant milestone in its international expansion, driven by official regulatory approvals in both the United Arab Emirates (UAE) and Turkey, alongside the first commercial sales for CellTolerance® in the region. These authorizations enable

Mauna Kea Technologies Announces Nomination of 3 New Directors

Mon, 18 May 2026 11:45:00 -0400

Their recognized expertise will help accelerate the strategic transformation launched in 2025

Subject to approval at upcoming Annual General Meeting

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces that the appointments of Ms. Elsy Boglioli Hofman, Mr. Richard Di Benedetto, and Mr. Randall Stanicky to its Board of Directors will be submitted for shareholder approval at the Annual General Meeting to be held on June 4, 2026. Internet voting opened today (details below).

If approved by shareholders, Mr. Richard Di

Mauna Kea Technologies Announces Nomination of 3 New Directors

Mon, 18 May 2026 11:45:00 -0400

Their recognized expertise will help accelerate the strategic transformation launched in 2025

Subject to approval at upcoming Annual General Meeting

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces that the appointments of Ms. Elsy Boglioli Hofman, Mr. Richard Di Benedetto, and Mr. Randall Stanicky to its Board of Directors will be submitted for shareholder approval at the Annual General Meeting to be held on June 4, 2026. Internet voting opened today (details below).

If approved by shareholders, Mr. Richard Di

Mauna Kea Technologies Announces Nomination of 3 New Directors

Mon, 18 May 2026 11:45:00 -0400

Their recognized expertise will help accelerate the strategic transformation launched in 2025

Subject to approval at upcoming Annual General Meeting

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces that the appointments of Ms. Elsy Boglioli Hofman, Mr. Richard Di Benedetto, and Mr. Randall Stanicky to its Board of Directors will be submitted for shareholder approval at the Annual General Meeting to be held on June 4, 2026. Internet voting opened today (details below).

If approved by shareholders, Mr. Richard Di

Mauna Kea Technologies Announces Nomination of 3 New Directors

Mon, 18 May 2026 11:45:00 -0400

Their recognized expertise will help accelerate the strategic transformation launched in 2025

Subject to approval at upcoming Annual General Meeting

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces that the appointments of Ms. Elsy Boglioli Hofman, Mr. Richard Di Benedetto, and Mr. Randall Stanicky to its Board of Directors will be submitted for shareholder approval at the Annual General Meeting to be held on June 4, 2026. Internet voting opened today (details below).

If approved by shareholders, Mr. Richard Di

Mauna Kea Technologies Announces Nomination of 3 New Directors

Mon, 18 May 2026 11:45:00 -0400

Their recognized expertise will help accelerate the strategic transformation launched in 2025

Subject to approval at upcoming Annual General Meeting

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces that the appointments of Ms. Elsy Boglioli Hofman, Mr. Richard Di Benedetto, and Mr. Randall Stanicky to its Board of Directors will be submitted for shareholder approval at the Annual General Meeting to be held on June 4, 2026. Internet voting opened today (details below).

If approved by shareholders, Mr. Richard Di

Mauna Kea Technologies Announces Nomination of 3 New Directors

Mon, 18 May 2026 11:45:00 -0400

Their recognized expertise will help accelerate the strategic transformation launched in 2025

Subject to approval at upcoming Annual General Meeting

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces that the appointments of Ms. Elsy Boglioli Hofman, Mr. Richard Di Benedetto, and Mr. Randall Stanicky to its Board of Directors will be submitted for shareholder approval at the Annual General Meeting to be held on June 4, 2026. Internet voting opened today (details below).

If approved by shareholders, Mr. Richard Di

Mauna Kea Technologies Announces Nomination of 3 New Directors

Mon, 18 May 2026 11:45:00 -0400

Their recognized expertise will help accelerate the strategic transformation launched in 2025

Subject to approval at upcoming Annual General Meeting

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces that the appointments of Ms. Elsy Boglioli Hofman, Mr. Richard Di Benedetto, and Mr. Randall Stanicky to its Board of Directors will be submitted for shareholder approval at the Annual General Meeting to be held on June 4, 2026. Internet voting opened today (details below).

If approved by shareholders, Mr. Richard Di

Mauna Kea Technologies Announces Nomination of 3 New Directors

Mon, 18 May 2026 11:45:00 -0400

Their recognized expertise will help accelerate the strategic transformation launched in 2025

Subject to approval at upcoming Annual General Meeting

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces that the appointments of Ms. Elsy Boglioli Hofman, Mr. Richard Di Benedetto, and Mr. Randall Stanicky to its Board of Directors will be submitted for shareholder approval at the Annual General Meeting to be held on June 4, 2026. Internet voting opened today (details below).

If approved by shareholders, Mr. Richard Di

Mauna Kea Technologies Announces Nomination of 3 New Directors

Mon, 18 May 2026 11:45:00 -0400

Their recognized expertise will help accelerate the strategic transformation launched in 2025

Subject to approval at upcoming Annual General Meeting

PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces that the appointments of Ms. Elsy Boglioli Hofman, Mr. Richard Di Benedetto, and Mr. Randall Stanicky to its Board of Directors will be submitted for shareholder approval at the Annual General Meeting to be held on June 4, 2026. Internet voting opened today (details below).

If approved by shareholders, Mr. Richard Di

StreetInsider.com News Articles

Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026

Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026

Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026

Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026

Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying “Triple Healing”, a Cellvizio®— Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Col

Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying “Triple Healing”, a Cellvizio®— Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Col

Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying “Triple Healing”, a Cellvizio®— Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Col

Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance® Commercial Installation

Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance® Commercial Installation

Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance® Commercial Installation

Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance® Commercial Installation

Mauna Kea Technologies Announces Nomination of 3 New Directors

Mauna Kea Technologies Announces Nomination of 3 New Directors

Mauna Kea Technologies Announces Nomination of 3 New Directors

Mauna Kea Technologies Announces Nomination of 3 New Directors

Mauna Kea Technologies Announces Nomination of 3 New Directors

Mauna Kea Technologies Announces Nomination of 3 New Directors

Mauna Kea Technologies Announces Nomination of 3 New Directors

Mauna Kea Technologies Announces Nomination of 3 New Directors

Mauna Kea Technologies Announces Nomination of 3 New Directors